Mark Massaro Analyst PerformanceManaging Director, Senior Equity Research Analyst at BTIG ResearchMark Massaro is a stock analyst at BTIG Research focused in the medical sector, covering 32 publicly traded companies. Over the past year, Mark Massaro has issued 76 stock ratings, including buy, hold, and sell recommendations. While full access to Mark Massaro's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Mark Massaro's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings256 Last 11 YearsBuy Recommendations89.60% 224 Buy RatingsCompanies Covered32 Unique Companies Ratings Distribution250RatingsDistribution of strong buy, buy, hold, and sell ratings by Mark Massaro.RatingPercentageCount Strong Buy0.0%0 ratings Buy89.6%224 ratings Hold9.6%24 ratings Sell0.8%2 ratingsOut of 250 total stock ratings issued by Mark Massaro at BTIG Research, the majority (89.6%) have been Buy recommendations, followed by 9.6% Hold and 0.8% Sell.Best & Worst CallsBest Call0000.0%TTOOFeb 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%WGSJan 2022Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ78.1% of companies on NASDAQ25 companiesNYSE15.6% of companies on NYSE5 companiesOTCMKTS6.3% of companies on OTCMKTS2 companiesMark Massaro, an analyst at BTIG Research, currently covers 32 companies listed on NASDAQ, NYSE and OTCMKTS, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical29 companies90.6%Services2 companies6.3%Computer and Technology1 company3.1%Mark Massaro of BTIG Research specializes in stock coverage within the Medical sector, with additional focus on Services and Computer and Technology companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE7 companies21.9%MEDICAL SERVICES5 companies15.6%MED INSTRUMENTS4 companies12.5%MED PRODUCTS4 companies12.5%MEDICAL INFO SYS3 companies9.4%SERVICES – HEALTH2 companies6.3%MED - GENERIC DRG1 company3.1%MED - DRUGS1 company3.1%MEDICAL LABORATORIES1 company3.1%SURGICAL & MEDICAL INSTRUMENTS1 company3.1%MED - OUTP/HM CRE1 company3.1%DIAGNOSTIC SUBSTANCES1 company3.1%MED/DENTAL - SUPP1 company3.1% About Mark MassaroMark Massaro is a Managing Director and BTIG Life Science and Diagnostic Tools Analyst. Prior to BTIG, he served as the Chief Financial Officer at ArcherDX, Inc., an oncology diagnostics and pharmaceutical services company, which was acquired by Invitae Corporation. Previously, Mr. Massaro was a Managing Director and Senior Equity Research Analyst within Diagnostics and Life Science Tools at Canaccord Genuity, where he spent more than eight years focused on high-growth, precision medicine and next-generation sequencing companies, as well as molecular and point-of-care diagnostics, reference labs and animal health. He was named a “Rising Star” in Institutional Investor’s All America Survey for life science and diagnostics tools in October 2016. Earlier in his career, Mr. Massaro was an Associate Equity Analyst within Healthcare Services at Avondale Partners and held corporate finance and financial reporting roles at Dell EMC and Fidelity Investments. He earned an MBA from Babson College and a BA in economics and Spanish from the University of Massachusetts – Amherst.Follow on LinkedIn Mark Massaro's Ratings History at BTIG Research Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsLUCDLucid Diagnostics5/15/2026Reiterated Rating$1.02$2.50Buy$0.0000.00% ROIMDXHMDxHealth5/14/2026Lower Price Target$1.95$4.00Buy$0.0000.00% ROICSTLCastle Biosciences5/13/2026Lower Price Target$18.63$40.00Buy$0.0000.00% ROIXGNExagen5/12/2026Lower Price Target$3.98$8.00Buy$0.0000.00% ROIPSNLPersonalis5/11/2026Lower Price Target$5.98$11.00Buy$0.0000.00% ROINTRANatera5/11/2026Lower Price Target$200.24$250.00Buy$0.0000.00% ROICAICaris Life Sciences5/8/2026Lower Price Target$19.84$32.00Buy$0.0000.00% ROITEMTempus AI5/8/2026Lower Price Target$49.02$80.00Buy$0.0000.00% ROIBLLNBilliontoone5/7/2026Lower Price Target$81.40$130.00Buy$0.0000.00% ROIADPTAdaptive Biotechnologies5/6/2026Reiterated Rating$13.78$22.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. SOPHSOPHiA GENETICS5/6/2026Reiterated Rating$5.07$8.00Buy$0.0000.00% ROIWGSGeneDx5/5/2026Lower Price Target$67.93$90.00Buy$0.0000.00% ROICERSCerus5/1/2026Upgrade$2.03$4.00Buy$0.0000.00% ROICDNACareDx4/29/2026Boost Price Target$21.91$28.00Buy$0.0000.00% ROISOPHSOPHiA GENETICS4/15/2026Boost Price Target$4.96$8.00Buy$0.0000.00% ROILUCDLucid Diagnostics3/30/2026Reiterated Rating$1.12$2.50Buy$0.0000.00% ROIEXASExact Sciences3/24/2026Reiterated Rating$104.91Neutral$0.0000.00% ROIDNAGinkgo Bioworks3/12/2026Lower Price Target$6.84$5.00Sell$0.0000.00% ROIXGNExagen3/10/2026Lower Price Target$3.33$9.00Buy$0.0000.00% ROIBLLNBilliontoone3/5/2026Lower Price Target$80.83$140.00Buy$0.0000.00% ROISOPHSOPHiA GENETICS3/3/2026Reiterated Rating$4.04$7.00Buy$0.0000.00% ROICAICaris Life Sciences2/27/2026Lower Price Target$19.24$38.00Buy$0.0000.00% ROIZTSZoetis2/26/2026Reiterated Rating$129.15$160.00Buy$0.0000.00% ROICDNACareDx2/25/2026Boost Price Target$18.46$26.00Buy$0.0000.00% ROITEMTempus AI2/25/2026Lower Price Target$57.95$90.00Buy$0.0000.00% ROIWGSGeneDx2/24/2026Lower Price Target$87.08$170.00Buy$0.0000.00% ROIGHGuardant Health2/20/2026Boost Price Target$106.38$145.00Buy$0.0000.00% ROIXGNExagen2/17/2026Lower Price Target$3.28$10.00Buy$0.0000.00% ROIPSNLPersonalis2/11/2026Boost Price Target$8.90$13.00Buy$0.0000.00% ROIADPTAdaptive Biotechnologies2/6/2026Boost Price Target$16.47$22.00Buy$0.0000.00% ROIIDXXIDEXX Laboratories2/3/2026Lower Price Target$639.60$800.00Buy$0.0000.00% ROIPSNLPersonalis1/9/2026Reiterated Rating$8.38$12.00Buy$0.0000.00% ROIMDXHMDxHealth12/23/2025Reiterated Rating$3.40$7.00Buy$0.0000.00% ROIGHGuardant Health12/12/2025Boost Price Target$101.38$140.00Buy$0.0000.00% ROIWGSGeneDx12/12/2025Boost Price Target$155.37$200.00Buy$0.0000.00% ROICSTLCastle Biosciences12/12/2025Boost Price Target$37.97$50.00Buy$0.0000.00% ROIBLLNBilliontoone12/10/2025Reiterated Rating$109.53$160.00Buy$0.0000.00% ROINTRANatera12/5/2025Boost Price Target$244.55$260.00Buy$0.0000.00% ROIZTSZoetis12/3/2025Reiterated Rating$124.44$160.00Buy$0.0000.00% ROIBLLNBilliontoone12/1/2025Initiated Coverage$130.18$160.00Buy$0.0000.00% ROIIran's New Leader Just Said Something That Should Terrify Every American (Ad)Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.Claim your free copy of The Great Gold Reset report todayBLLNBilliontoone12/1/2025Initiated Coverage$113.04$160.00Buy$0.0000.00% ROITEMTempus AI11/25/2025Boost Price Target$76.06$105.00Buy$0.0000.00% ROIEXASExact Sciences11/20/2025Downgrade$100.99Neutral$0.0000.00% ROIMDXHMDxHealth11/13/2025Boost Price Target$4.12$7.00Buy$0.0000.00% ROIZTSZoetis11/12/2025Lower Price Target$120.09$160.00Buy$0.0000.00% ROIPSNLPersonalis11/11/2025Boost Price Target$8.63$12.00Buy$0.0000.00% ROIXGNExagen11/10/2025Boost Price Target$9.56$15.00Buy$0.0000.00% ROISOPHSOPHiA GENETICS11/10/2025Boost Price Target$4.37$7.00Buy$0.0000.00% ROINTRANatera11/7/2025Boost Price Target$198.48$230.00Buy$0.0000.00% ROIADPTAdaptive Biotechnologies11/6/2025Boost Price Target$15.56$21.00Buy$0.0000.00% ROICDNACareDx11/6/2025Boost Price Target$16.53$25.00Buy$0.0000.00% ROITEMTempus AI11/5/2025Reiterated Rating$84.49$96.00Buy$0.0000.00% ROICSTLCastle Biosciences11/4/2025Boost Price Target$31.63$38.00Buy$0.0000.00% ROIIDXXIDEXX Laboratories11/4/2025Boost Price Target$722.94$830.00Buy$0.0000.00% ROIEXASExact Sciences11/4/2025Boost Price Target$66.98$85.00Buy$0.0000.00% ROIGHGuardant Health10/30/2025Boost Price Target$72.27$100.00Buy$0.0000.00% ROIWGSGeneDx10/29/2025Boost Price Target$137.47$165.00Buy$0.0000.00% ROINTRANatera10/23/2025Boost Price Target$192.51$210.00Buy$0.0000.00% ROITEMTempus AI10/22/2025Boost Price Target$89.10$96.00Buy$0.0000.00% ROIPSNLPersonalis10/22/2025Boost Price Target$9.57$11.00Buy$0.0000.00% ROIWGSGeneDx10/22/2025Boost Price Target$121.77$140.00Buy$0.0000.00% ROIXGNExagen10/22/2025Boost Price Target$11.69$13.00Buy$0.0000.00% ROIEXASExact Sciences10/22/2025Boost Price Target$63.41$75.00Buy$0.0000.00% ROIADPTAdaptive Biotechnologies10/22/2025Boost Price Target$17.35$19.00Buy$0.0000.00% ROIGHGuardant Health9/25/2025Set Price Target$61.04$80.00$0.0000.00% ROICDNACareDx9/23/2025Reiterated Rating$14.99$22.00Buy$0.0000.00% ROIGHGuardant Health9/22/2025Reiterated Rating$59.15$70.00Buy$0.0000.00% ROICDNACareDx9/12/2025Reiterated Rating$13.53$22.00Buy$0.0000.00% ROILUCDLucid Diagnostics9/5/2025Boost Price Target$1.38$2.50Buy$0.0000.00% ROIGHGuardant Health9/4/2025Boost Price Target$59.08$70.00Buy$0.0000.00% ROIDNAGinkgo Bioworks8/25/2025Boost Price Target$12.51$9.00Sell$0.0000.00% ROITEMTempus AI8/20/2025Boost Price Target$73.08$85.00Buy$0.0000.00% ROIEXASExact Sciences8/12/2025Lower Price Target$41.52$60.00Buy$0.0000.00% ROIMXCTMaxCyte8/11/2025Reiterated Rating$1.38Neutral$0.0000.00% ROITEMTempus AI8/8/2025Initiated Coverage$58.74$60.00Buy$0.0000.00% ROIPSNLPersonalis8/6/2025Set Price Target$4.52$6.00$0.0000.00% ROITEMTempus AI4/21/2025Initiated Coverage$40.42$60.00Buy$00.0000.00% ROIMXCTMaxCyte3/12/2025Set Price Target$3.47$6.00Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageMorgan StanleyJefferies Financial GroupStifel NicolausOppenheimerBerenberg BankRoth MkmWall Street ZenUBS GroupCitigroupBarclaysWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.The Goldman Sachs GroupTD Cowen Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.